MEK1/2 and c-Myc:MAX Cooperate to Regulate TERT in Human Pluripotent Stem Cells

Study Background and Research Question

Telomerase activity, governed by the expression of its catalytic subunit TERT, is essential for the self-renewal and long-term proliferative capacity of human pluripotent stem cells (hPSCs). While telomerase activation is a hallmark of stemness, its regulation—especially the transcriptional control of TERT—remains incompletely understood in human stem cells. Prior work has linked MAPK signaling to telomerase regulation in induced pluripotent cells, but the direct connections and mechanisms in bona fide human embryonic stem cells (hESCs) required clarification. The reference study (Kotian et al., 2024) addresses how MEK1/2 kinases and the c-Myc:MAX transcription factor complex interact to prevent polycomb-mediated repression of TERT, thereby maintaining telomerase activity in hPSCs.

Key Innovation from the Reference Study

The central advance of this study is the elucidation of a dual regulatory mechanism: MEK1/2 kinases and the c-Myc:MAX complex act in concert to keep the TERT promoter in an active state by opposing polycomb repressive complex 2 (PRC2) activity. Specifically, the authors demonstrate that inhibition of MEK/ERK signaling promotes deposition of the repressive histone mark H3K27me3 at the TERT promoter, while loss of c-Myc:MAX dimerization similarly leads to TERT repression and increased PRC2 recruitment. This joint regulation reveals a previously unrecognized safeguard of telomerase expression in stem cells, with implications for both stem cell maintenance and telomere biology disorders.

Methods and Experimental Design Insights

The study employed a combination of pharmacological inhibition, chromatin immunoprecipitation (ChIP), and transcriptional profiling in hESC cultures. Key approaches included:

• Use of selective MEK1/2 (MEKi) and ERK1/2 (ERKi) kinase inhibitors to dissect MAPK pathway contributions.
• Assessment of TERT mRNA levels by quantitative RT-PCR following inhibitor treatments.
• ChIP assays targeting histone modifications—specifically H3K27me3 (repressive) and H3K27ac (active)—at the TERT proximal promoter.
• Application of PRC2 inhibitors to test reversibility of TERT repression.
• Inhibition of c-Myc:MAX dimerization using low doses of a small-molecule inhibitor to evaluate effects on TERT transcription and associated chromatin changes.
• ChIP for MAX occupancy at the TERT promoter to link dimerization status with promoter binding.

This multifaceted design allowed the authors to connect signal transduction, transcription factor dimerization, and chromatin state to TERT regulation in a physiologically relevant model.

Core Findings and Why They Matter

• MEK/ERK Activity Maintains TERT Expression: Pharmacological inhibition of MEK1/2 or ERK1/2 in hESCs led to a significant reduction in TERT mRNA levels, correlating with increased H3K27me3 and loss of H3K27ac at the TERT promoter (Kotian et al., 2024).
• Polycomb Repression as a Downstream Effector: The accumulation of H3K27me3 upon MEK/ERK inhibition was partially reversed by PRC2 inhibition, indicating that MAPK signaling restrains polycomb activity at TERT.
• c-Myc:MAX Dimerization is Crucial: Disruption of c-Myc:MAX dimerization recapitulated the effects of MEK/ERK inhibition, rapidly inducing H3K27me3 deposition and reducing TERT transcription. Loss of MAX recruitment to the TERT promoter further supported the functional importance of this dimerization event.
• Integration of Signaling and Transcriptional Control: The results position c-Myc:MAX as a necessary effector downstream of MEK/ERK for TERT promoter activation, highlighting the integration of signal transduction and transcription factor availability in stem cell telomere maintenance.

These findings have broad significance for understanding how stem cells preserve their proliferative capacity and how telomere biology disorders might arise from disruptions in these regulatory networks.

Comparison with Existing Internal Articles

Several internal resources contextualize the use of c-Myc-Max dimerization inhibitors, particularly 10058-F4, in mechanistic and translational workflows. For example, this article explores the landscape of c-Myc-Max dimerization inhibition, providing strategic insights into DNA repair, oncogenic transcription, and apoptosis assay workflows. Another resource (internal protocol guide) details practical protocol enhancements and troubleshooting for 10058-F4 in leukemia and prostate cancer research models. The reference study by Kotian et al. extends these themes by showing that c-Myc:MAX inhibition also impacts telomerase regulation and chromatin state in non-cancerous stem cells, suggesting a broader relevance for small-molecule dimerization inhibitors beyond oncogenic contexts. This complements prior work on apoptosis and transcription factor inhibition—see apoptosis assay applications—by connecting c-Myc:MAX targeting to developmental gene regulation.

Limitations and Transferability

While the study leverages hESCs as a model for human pluripotency, transferability to adult stem cells or somatic contexts remains to be validated. The pharmacological approaches, while rigorous, may have off-target effects that complicate interpretation. Notably, the specific small-molecule c-Myc:MAX dimerization inhibitor used in the study is not named, though the workflow closely parallels the properties and application strategies of 10058-F4 described in internal and product literature. Direct evidence in disease-relevant or in vivo models is limited, and future studies will be needed to assess whether these mechanisms operate in aging, cancer, or regenerative therapy settings. Additionally, while the link between chromatin state and TERT expression is robust, the precise intermediate steps and other potential cofactors remain under investigation.

Protocol Parameters

• MEK1/2 or ERK1/2 inhibitor treatment: Apply selective kinase inhibitors at established concentrations for 24–48 hours in hESC culture to assess effects on TERT expression and chromatin state.
• c-Myc:MAX dimerization inhibitor: Use low micromolar concentrations; titrate according to cell type and desired temporal resolution (as per product recommendations and reference workflows).
• ChIP workflow: Harvest cells after 12–48 hours of inhibitor treatment for ChIP targeting H3K27me3, H3K27ac, and MAX occupancy at the TERT promoter.
• PRC2 inhibition: Where testing reversibility, apply PRC2 inhibitors concurrently or following MEK/ERK inhibition for 24 hours before endpoint analyses.
• RNA quantification: Extract total RNA and quantify TERT mRNA via qRT-PCR, normalizing to housekeeping controls.

These parameters are grounded in the experimental design of the reference study and can be adapted for related stem cell and transcriptional regulation research.

Research Support Resources

To support mechanistic studies of c-Myc:MAX function and telomerase regulation, researchers may utilize the 10058-F4 C-Myc-Max dimerization inhibitor (SKU A1169), a validated small-molecule tool for disrupting c-Myc-driven transcriptional programs in cell and animal models. For apoptosis assay workflows, c-Myc transcription factor inhibition, or telomerase-targeted research in leukemia and prostate cancer systems, 10058-F4 provides a well-characterized option with established solubility and storage guidelines. Product specifications and workflow recommendations are available from APExBIO to facilitate reproducible experimental design. As always, researchers should validate protocol parameters in their specific biological context.